Ultrahuman's $70M raise to expand its global healthtech platform resurfaces

Indian smart-ring maker Ultrahuman raised $70 million in a September 2026 move to scale its sensing, AI, blood-testing and continuous glucose-monitoring offerings globally. The company says it was profitable in FY25, reporting ₹564.7 crore in operating revenue and ₹71.5 crore in net profit.

— Source publishedThu, 3 Sept, 2026, 23:30 IST·First seen Sun, 27 Sept, 2026, 06:03 IST·Source Inc42 · D2C

What happened

Indian smart-ring maker Ultrahuman raised $70 million to expand sensing, AI, blood testing and continuous glucose monitoring globally. The company reported FY25

Key facts

  • $70 million fresh funding (nearly ₹662 crore)
  • More than $173 million total funding to date
  • FY25 net profit: ₹71.5 crore
  • FY24 net loss: ₹37.7 crore
  • FY25 operating revenue: ₹564.7 crore
  • FY24 operating revenue: ₹104.6 crore
  • FY25 revenue growth: nearly 5x
  • About 0.1% of users affected by wellness-data leak
  • India healthtech market projected at $106 billion by 2033

Why this matters

Ultrahuman’s funded expansion across wearables, diagnostics and continuous monitoring makes it a more consequential partnership or acquisition target in connected health.

What to watch

  • New country launches, retail-channel agreements or local fulfillment announcements.
  • Evidence of subscription growth, repeat blood-test purchases and CGM attach rates.
  • Pricing changes or new hardware launches from Oura, Samsung, Apple, Garmin and Xiaomi.
  • Clinical studies, FDA/CE approvals, health-data privacy developments or tighter wearable-health regulations.
  • Whether reported profitability persists after international sales and marketing spending ramps.
  • Inventory availability, delivery times, return rates and customer-review trends in newly entered markets.
  • Expand direct-to-consumer fulfillment and selected premium retail distribution in North America, Europe and the Gulf.
  • Use funding to deepen AI-driven health insights and integrate ring data with glucose-monitoring and blood-test products.
  • Pursue partnerships with diagnostic labs, insurers, corporate wellness programs, gyms and longevity clinics.
  • Increase product development around sensor accuracy, battery life, women’s health, sleep, metabolic health and personalized coaching.
  • Invest in regulatory, privacy and clinical-validation capabilities to support healthcare-adjacent claims in new markets.